Stock analysis, AI verdict, fundamentals & technical signals
Rating: BUY AI Verdict: PROCEED
Price: $313.52 Analyst target: $346.75 Upside: 10.60%
LGND is in a strong uptrend (close 308.3 vs SMA50 242.57 and SMA200 132.81), near the 52w high of 326.63, with fundamentals supporting it: quarterly revenue growth +33.7%, earnings growth +825% YoY, 67.9% profit margin and forward PE 24.8. Insider cluster buying (3 distinct buyers, ~$1.43M vs $1.13M sold) is a bullish confirm, and the analyst target of 344.25 implies ~12% upside. No clear company-specific catalyst in the news (a single neutral item), so the move looks momentum/earnings-driven rather than panic.
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs globally. The company is headquartered in San Diego, California.
See the full interactive analysis & chart →Informational only — not investment advice.